Biomedical Engineering Reference
In-Depth Information
85. Lupo E, Locher R, Weisser B, Vetter W (1994) In vitro antioxidant activity of calcium
antagonists against LDL oxidation compared with
-tocopherol. Biochem Biophys Res
a
Commun 203:1803-1808
86. Berkels R, Breitenbach T, Bartels H, Taubert D, Roesenkranz A, Klaus W, Roesen R (2005)
Different antioxidative potencies of dihydropyridine calcium channel modulators in various
models. Vascul Pharmacol 42:145-152
87. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA (1997) Molecular determinants of
drug binding and action on
L
-type calcium channels. Annu Rev Pharmacol Toxicol
37:361-396
88. Manhold R, Steiner R, Hass W, Kaufman R (1978) Investigations on the structure-activity
relationships of verapamil. Naunyn Schmiedebergs Arch Pharmacol 302:217-226
89. Triulzi MO, Mattioli R, Signorini G, Cirino D, Esposti D, Aguggini G, Maggi GC (1990)
Effects of low-dose diltiazem on isovolumetric relaxation and contraction. G Ital Cardiol
20:1137-1143
90. Corelli F, Manetti F, Taft A, Campiani G, Nacci V, Botta M (1997) Diltiazem-like calcium
entry blockers: a hypothesis of the receptor-binding site based on a comparative molecular
field analysis model. J Med Chem 40:125-131
91. Campiani G, Garofalo A, Fiorini I, Botta M, Nacci V, Taft A, Chiarini A, Budriest R, Bruni
G, Romeo MR (1995) Pyrrolo[2,1-c][1,4]benzothiazines: synthesis, structure-activity
relationships, molecular modeling studies, and cardiovascular activity. J Med Chem
38:4393-4410
92. Kimball SD, Floyd DM, Das J, Hunt JT, Krapcho J, Rovnyak G, Duff KJ, Lee VG, Moquin
RV, Turk CF, Hedberg SA, Moreland S, Brittain RJ, McMullen DM, Normandin DE,
Cucinotta GG (1992) Benzazepinone calcium channel blockers. 4. Structure-activity over-
view and intracellular binding site. J Med Chem 35:780-793
93. Inoue H, Konda M, Hashiyama T, Otsuka H, Takahashi K, Gaino M, Date T, Aoe K,
Takeda M, Murata S, Narita H, Nagao T (1991) Synthesis of halogen-substituted
1,5-benzothiazepine derivatives and their vasodilating and hypotensive activities. J Med
Chem 34:675-687
94. Floyd DM, Kimball SD, Krapcho J, Das J, Turk CF, Moquin RV, Lago MW, Duff KJ, Lee
VG, White RE, Ridgewell RE, Moreland S, Brittain RJ, Normandin DE, Hedberg SA,
Cucinotta GG (1992) Benzazepinone calcium channel blockers. 2. Structure activity and
drug metabolism studies leading to potent antihypertensive agents. Comparison with
benzothiazepinones. J Med Chem 35:756-772
95. Das J, Floyd DM, Kimball SD, Duff KJ, Vu TC, Lago MW, Moquin RV, Lee VG, Gougoutas
JZ, Malley MF, Moreland S, Brittain RJ, Hedberg SA, Cucinotta GG (1992) Benzazepinone
calcium channel blockers. 3. Synthesis and structure-activity studies of 3-alkylbenza-
zepinones. J Med Chem 35:773-780
96. Clozel J, Ertel E, Ertel SJ (1997) Discovery and main pharmacological properties of
mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens
15:S17-S25
97. Van der Vring J, Cleophas T, Van der Wall E, Niemeyer M (1999) T-channel-selective
calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so
far: a review of published data. Am J Ther 6:229-233
98. Benardeau A, Ertel E (1997) Selective block of myocardial T-type calcium channels by
mibefradil: A comparison with the 1,4- dihydropyridine amlodipine. Adis International
Chester, UK
99. Ertel SI, Ertel EA, Clozel JP (1997) T-type Ca
2
รพ
channels and pharmacological blockade:
potential pathophysiological relevance. Cardiovasc Drugs Ther 11:723-739
100. Kobrin I, Bieska G, Charlon V, Lindberg E, Pordy R (1998) Anti-anginal and anti-ischemic
effects of mibefradil, a new T-typecCalcium channel antagonist. Cardiology 89:23-32
101. Asirvatham S, Sebastian C, Thadani U (1998) Choosing the most appropriate treatment for
stable angina: safety considerations. Drug Saf 19:23-44
